150 related articles for article (PubMed ID: 37729375)
1. The prognostic significance of the heterologous component in uterine carcinosarcomas.
Can B; Karataşli V; Çakir İ; Sayhan S; Hansu K; Kuru O
Rev Assoc Med Bras (1992); 2023; 69(9):e20230517. PubMed ID: 37729375
[TBL] [Abstract][Full Text] [Related]
2. Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter study.
Rosati A; Vargiu V; Certelli C; Arcieri M; Vizza E; Legge F; Cosentino F; Ferrandina G; Fanfani F; Scambia G; Corrado G
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6479-6488. PubMed ID: 36773091
[TBL] [Abstract][Full Text] [Related]
3. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
4. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
Cicin İ; Özatlı T; Türkmen E; Özturk T; Özçelik M; Çabuk D; Gökdurnalı A; Balvan Ö; Yıldız Y; Şeker M; Özdemir N; Yapar B; Tanrıverdi Ö; Günaydin Y; Menekşe S; Öksüzoğlu B; Aksoy A; Erdogan B; Bekir Hacıoglu M; Arpaci E; Sevinç A
Balkan Med J; 2016 Sep; 33(5):517-524. PubMed ID: 27761279
[TBL] [Abstract][Full Text] [Related]
5. Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study.
Kimyon Cömert G; Türkmen O; Boyraz G; Yalçın İ; Altın D; Karalök A; Şahin H; Taşkın S; Başaran D; Fırat Cuylan Z; Koyuncu K; Salman MC; Özgül N; Meydanlı MM; Turan T; Ortaç F; Yüce K
Balkan Med J; 2019 Jul; 36(4):229-234. PubMed ID: 30873825
[TBL] [Abstract][Full Text] [Related]
6. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Podzielinski I; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Matsuzaki S; Baba T; Satoh S; Shida M; Nishikawa T; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Fujiwara K; Hazama Y; Kadogami D; Moffitt MN; Takeuchi S; Nishimura M; Iwasaki K; Ushioda N; Johnson MS; Yoshida M; Hakam A; Li SW; Richmond AM; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Yamaguchi K; Oishi T; Kajiwara H; Hasegawa K; Yasuda M; Kawana K; Suda K; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Wakatsuki A; Sugiyama T; Pejovic T; Nagano T; Shimoya K; Andoh M; Shiki Y; Enomoto T; Sasaki T; Fujiwara K; Mikami M; Shimada M; Konishi I; Kimura T; Post MD; Shahzad MM; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Oncol; 2016 Jul; 27(7):1257-66. PubMed ID: 27052653
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: a systematic review and meta-analysis.
Kim Y; Kang GH; Kim H
J Gynecol Oncol; 2023 Nov; 34(6):e73. PubMed ID: 37417301
[TBL] [Abstract][Full Text] [Related]
8. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
11. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
13. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.
Garg G; Shah JP; Kumar S; Bryant CS; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Jul; 20(5):888-94. PubMed ID: 20606539
[TBL] [Abstract][Full Text] [Related]
14. How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?
Rovirosa A; Ascaso C; Ordi J; Arenas M; Valduvieco I; Lejarcegui JA; Pahisa J; Torne A; Biete A
Clin Transl Oncol; 2009 Oct; 11(10):681-7. PubMed ID: 19828411
[TBL] [Abstract][Full Text] [Related]
15. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
16. Prognostic features of surgical stage I uterine carcinosarcoma.
Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA
Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221
[TBL] [Abstract][Full Text] [Related]
17. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
19. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Enomoto T; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Surg Oncol; 2018 Sep; 25(9):2756-2766. PubMed ID: 29971677
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]